Pfizer Research Grant Request for Proposals: Pre-clinical Investigation of anti-TFPI-mediated Rebalancing Mechanisms in Non-Hemophilic Bleeding Disorders
Pfizer funds research into anti-TFPI-mediated hemostatic rebalancing for rare and non-hemophilic bleeding disorders to advance understanding and potential therapies.
Funder: Pfizer Inc.
Due Dates: July 1, 2026: Full application submission deadline (applications must be submitted by 23:59 Eastern Standard Time)
Funding Amounts: Up to $50,000 USD per project (plus up to $50,000 USD in study drug costs if applicable); maximum project length 1 year; total RFP budget $300,000 USD.
Summary: Supports preclinical research into anti-TFPI-mediated hemostatic rebalancing in rare and non-hemophilic bleeding disorders to advance foundational science and potential therapies.
Description
This grant opportunity from Pfizer Inc. is designed to support preclinical or foundational research that investigates the therapeutic potential and mechanisms of anti-TFPI-mediated hemostatic rebalancing in inherited or non-hemophilic bleeding disorders. The aim is to address scientific gaps and generate new data on TFPI modulation in disorders such as deficiencies in Factors II, V, VII, X, XI, von Willebrand disease, Glanzmann's thrombasthenia, or bleeding disorders of unknown cause (BDUC). The program encourages innovative, non-duplicative research that builds on existing work, with the goal of improving understanding of disease mechanisms and informing future therapies for these rare conditions. Proposals related to hemophilia A (FVIII deficiencies) and hemophilia B (FIX deficiencies) are not eligible.
